SCHEMBL5010672

SCHEMBL5010672

Cc1cccc(-n2nc(C(C)(C)C)cc2Nc2ccccc2C(=O)O)c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.59
MAPK13 O15264 10/20 0.59
MAPK12 P53778 10/20 0.59
MAPK11 Q15759 10/20 0.59
LMNA P02545 2/20 0.52
MEN1 O00255 1/20 0.52
AKR1B10 O60218 1/20 0.52
TRPA1 O75762 1/20 0.52
ABCB11 O95342 1/20 0.52
DHFR P00374 1/20 0.52
MPO P05164 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CHRM1 P11229 1/20 0.52
CYP2C9 P11712 1/20 0.52
AKR1B1 P15121 1/20 0.52
PTGS1 P23219 1/20 0.52
PTGS2 P35354 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010659 0.92 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL5005267 0.88 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL5010696 0.86 ADORA1 (0.54) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL5007721 0.86 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11GFER
SCHEMBL5007743 0.86 CLCN2 (0.51) MAPK14MAPK13MAPK12MAPK11GFER
SCHEMBL5010626 0.84 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL5008471 0.84 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11ADORA1
SCHEMBL14600217 0.83 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11GFER
SCHEMBL5008768 0.83 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11GFER
SCHEMBL5005515 0.83 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.